NVD-401 – Sildenafil OS
NVD-401 contains sildenafil, the leading PDE-5 inhibitor for the treatment of erectile dysfunction marketed under the brand name Viagra®.  NovaDel believes that an oral spray of sildenafil has the potential of a faster onset of action and a lower dose compared to tablets.

Current Status

NovaDel is completing development of a formulation of NVD-401 and plans to initiate human clinical studies in 2009.

About Erectile Dysfunction

Erectile dysfunction occurs in ~18% of the male population with prevalence of over 50% in men over 65 years of age.  PDE-5 inhibitors are effective in ~75 of the erectile dysfunction population.  Sildenafil is the most popular molecule with over 50% market share in a erectile dysfunction market of over $3 billion.